Bei lu pharmaceutical industry to Yu Hengrui to grab the first imitation! The 15 billion-year-old imager market is back on the ups and downs

Recently, CDE official website shows that Beijing Bei lu pharmaceutical industry's niobol injection imitation 4 classes of listing applications were accepted.
meters intranet data show that in 2019 China's public medical institutions terminal imager sales of more than 15 billion yuan, in the product TOP20, the injection of niobol ranked 18th, the manufacturer of only Bayer.
has grown rapidly in recent years, with growth of more than 70% in 2019.
, Jiangsu Hengrui Pharmaceutical's niobol injections were submitted for listing in a generic category of 4.
Source: One-click access to MiNet data show that in recent years, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal shadow agent sales growth rate of more than 10%, in 2019 has exceeded 15 billion yuan.
18th place in the TOP20, a product with only one Bayer manufacturer, with sales up more than 70% year-on-year in 2019.
source: MED2.0 China Drug Review Database Up to now, the injection of niobol has Beijing Beiland Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals to copy 4 categories of applications submitted for listing, in the review and approval (in the drug review center), after approval will be treated as a consistent evaluation.
data source: CDE official website, Mi Net database original title: This Beijing pharmaceutical company to Yan Hengrui to grab the first imitation! The 15 billion-year-old imager market is back on the ups and downs